New Drug Leramistat Enters Phase 2 Trial to Reverse Age-Related Muscle Loss
Istesso launches a clinical trial of leramistat, a regenerative therapy targeting sarcopenia — the muscle loss affecting 1 in 3 adults over 60.
Summary
A London-based biotech called Istesso has started a Phase 2 clinical trial testing leramistat, an oral drug designed to reverse muscle loss in people with sarcopenia linked to rheumatoid arthritis. Sarcopenia — the gradual decline in muscle mass and strength — affects roughly one in three adults over 60 and raises the risk of falls, fractures, and early death. Unlike existing treatments that only manage symptoms, leramistat works by activating the body's own repair systems through a mechanism called mitochondrial complex I modulation. Earlier studies in rheumatoid arthritis patients showed reductions in disability and fatigue, and animal studies showed muscle function improvements beyond those seen in younger mice. The new trial will test whether these benefits translate to measurable gains in human muscle health and physical function.
Detailed Summary
Muscle loss is one of aging's most underappreciated threats, and a new clinical trial is trying to change that. Istesso, a regenerative medicine company based in London, has launched a Phase 2 study — called IST-03 — testing its lead drug leramistat in people with sarcopenia associated with rheumatoid arthritis. The trial aims to determine whether the oral therapy can meaningfully improve muscle quality, repair capacity, and physical function in patients experiencing disease-related muscle decline.
Sarcopenia affects an estimated one in three adults over 60. It is not simply a cosmetic concern — it directly increases risk of falls, fractures, hospitalization, disability, and death. Despite its enormous burden on aging populations globally, no medicines are currently approved specifically to treat it. That regulatory gap has intensified interest in therapies that go beyond slowing decline and instead restore tissue function.
Leramistat belongs to a new class called mitochondrial complex I modulators. Rather than suppressing inflammation or masking symptoms, it is designed to activate the body's own regenerative repair systems. The hypothesis is that by restoring cellular energy and repair signaling, damaged muscle tissue can recover and rebuild. Previous clinical work in rheumatoid arthritis patients showed encouraging signals: reductions in disability, fatigue, and biomarkers associated with muscle wasting. Preclinical studies in aged mice showed muscle performance improvements that exceeded levels seen in younger animals at baseline.
For the longevity field, the significance here extends beyond one drug or one disease. Sarcopenia frequently co-occurs with Alzheimer's, heart failure, and fibrotic disorders, suggesting that a regenerative therapy effective in one context could have broader applications. Researchers increasingly view the body's declining repair capacity as a root driver of multiple age-related conditions simultaneously.
Important caveats apply. Animal data rarely translates cleanly to humans, and Phase 2 trials primarily assess safety and early efficacy signals rather than confirming clinical benefit. Results are not yet available, and leramistat remains experimental. Still, this trial represents a meaningful advance in the effort to treat muscle aging as a medical condition rather than an inevitable consequence of growing old.
Key Findings
- Leramistat enters Phase 2 trial targeting sarcopenia, a condition affecting 1 in 3 adults over age 60 with no approved treatments.
- The drug activates mitochondrial repair pathways to regenerate muscle tissue rather than simply managing symptoms.
- Earlier RA patient studies showed reduced disability, fatigue, and muscle-loss biomarkers — supporting this new muscle-focused trial.
- Preclinical data showed aged mice on leramistat achieved muscle function exceeding younger untreated mice at baseline.
- Sarcopenia co-occurs with rheumatoid arthritis, Alzheimer's, and heart failure, suggesting broad potential for a regenerative approach.
Methodology
This is a news report summarizing a company announcement of a Phase 2 clinical trial initiation. The source, Longevity.Technology, is a specialist publication covering aging science; it cites Istesso's trial announcement and preclinical data presentations as its evidence basis. No peer-reviewed trial results are available yet, as the study has just launched.
Study Limitations
No human efficacy data from IST-03 is available yet — the trial has only just initiated enrollment. Animal model results cited are promising but do not guarantee human translation. Readers should await peer-reviewed publications from the completed trial before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.